Deal overview

Deal overview
Target BIOVERATIV INC
Bidder SANOFI SA
Price £90.00 Full version or £25.00 Light version
Publication Date Jan 22, 2018
Abstract On 22 January 2018, the French healthcare and pharmaceuticals company Sanofi SA ("Sanofi") announced a recommended offer for the quoted US-based biopharmaceuticals group Bioverativ Inc ("Bioverativ"). The offer of US$ 105 per share in cash represented an equity value of approximately US$ 11.4 billion. The offer was expected to commence in February 2018.
Number of pages (Full version) 9
Number of pages (Light version) 2
Format Adobe Acrobat (Download Acrobat Reader)
Free Sample Click Here to Download

Purchase this report

Accepted credit cards: Visa, America Express, Master Card

Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.

Search for Deals

Search over 70 million deal reports on more than 550,000 public and private companies. (copy)

Back to search results

Page Time: 0.013721s